What is Sinopia Biosciences?
Sinopia Biosciences is dedicated to transforming the landscape of Parkinson's disease treatment through pioneering research and development initiatives. Operating from its base in San Diego, California, the company is committed to advancing its pipeline of therapeutic solutions designed to address the complex challenges associated with Parkinson's disease. Their strategic focus includes engaging with healthcare providers and organizations actively involved in the management and treatment of this neurodegenerative disorder. Sinopia Biosciences also actively seeks strategic alliances and partnerships to amplify its impact and accelerate progress in the field.
How much funding has Sinopia Biosciences raised?
Sinopia Biosciences has raised a total of $5.4M across 3 funding rounds:
Debt
$82K
Grant
$3.3M
Other Financing Round
$2M
Debt (2021): $82K with participation from PPP
Grant (2023): $3.3M led by National Institute of Neurological Disorders and Stroke
Other Financing Round (2023): $2M supported by The Michael J. Fox Foundation for Parkinson’s Research
Key Investors in Sinopia Biosciences
National Institute of Neurological Disorders and Stroke
The National Institute of Neurological Disorders and Stroke (NINDS) is a U.S. government organization dedicated to advancing research and health related to brain and nervous system disorders. It provides funding opportunities, conducts clinical trials, and offers educational resources for patients, caregivers, and health professionals.
The Michael J. Fox Foundation for Parkinson’s Research
The Michael J. Fox Foundation for Parkinson’s Research is a leading non-profit organization dedicated to accelerating the discovery of a cure for Parkinson's disease. It funds research into novel treatments and therapies, aiming to improve the lives of those affected by the condition.
PPP
Public-Private Partnership
What's next for Sinopia Biosciences?
The substantial enterprise-level investment in Sinopia Biosciences indicates a strong market confidence in their innovative approach to Parkinson's disease. This capital infusion is expected to fuel the acceleration of their research pipeline, potentially enabling critical clinical trials and further development of their therapeutic candidates. The company's strategic positioning, coupled with this significant financial backing, suggests a trajectory towards scaling operations and solidifying its role as a key player in the neurological disorder therapeutics sector. Future developments will likely focus on advancing their lead programs and expanding their research collaborations.
See full Sinopia Biosciences company page
